Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 23:10:20503121221145605.
doi: 10.1177/20503121221145605. eCollection 2022.

Effectiveness of glycopyrronium bromide in the treatment of small airway dysfunction: A retrospective study

Albino Petrone  1 , Corrado Pelaia  2 , Michela Quartieri  1 , Ludovico Petrone  2 , Giuseppe Francesco Rago  1 , Clementina Columbro  1 , Girolamo Pelaia  2
Affiliations

Effectiveness of glycopyrronium bromide in the treatment of small airway dysfunction: A retrospective study

Albino Petrone et al. SAGE Open Med. .

Abstract

Objective: Glycopyrronium bromide has a quaternary ammonium structure and a low oral bioavailability, which reduces its systemic effects; it acts through a bronchodilating blockade of muscarinic receptors. The aim of this retrospective study was to analyze a possible relationship between the changes in the small airways and the efficacy of a bronchodilation with glycopyrronium bromide; exercise tolerance was also assessed, by performing the six-minute walking test.

Methods: Forty-one patients were identified (23 females/18 males; mean age 66.82 ± 9.75 years), with a normal forced expiratory volume in 1 s (FEV1)/forced vital capacity ratio of 77.45% ± 4.86%, a reduced forced mid-expiratory flow between 25% and 75% of forced vital capacity (FEF25-75) of 42.9% ± 10.5%, with an increased residual volume/total lung capacity ratio of 132.68% ± 6.41%, FEV1 1.85 ± 0.54 L, forced vital capacity 2.39 ± 0.71 L, airway resistance (sR tot) 168.18% ± 42.5%, total lung capacity 98.28% ± 8.9%, six-minute walking test distance 318.3 ± 36.6 m, modified British Medical Research Council dyspnea scale 1.48 ± 0.77. All patients were initiated with glycopyrronium bromide 50 μg/die and reassessed after 4 months.

Results: After the treatment with glycopyrronium bromide, a significant improvement was noted regarding forced vital capacity (p = 0.04), FEF25-75 (p < 0.001), sR tot (p < 0.001), residual volume/total lung capacity ratio (p < 0.001) with reduction of dynamic hyperinflation, the significant increase of the distance covered during the six-minute walking test (p < 0.001), and modified British Medical Research Council (p < 0.001) showed enhanced exercise tolerance. FEV1 improved, but the difference was not statistically significant.

Conclusions: Small airway dysfunction is associated with bronchodilator responsiveness. Glycopyrronium bromide has proven to be capable of inducing favorable effects on lung hyperinflation and its functional and clinical consequences, with a decrease in dyspnea and an increase in exercise capacity. The use of anticholinergic drugs is useful in the management of small airway disease.

Keywords: Anticholinergic drugs; COPD; bronchodilator; glycopyrronium bromide; small airway.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Pelaia G, Maselli R, Gallelli L. Pharmacologic rationale, efficacy and safety of fixed-dose co-formulation of indacaterol and glycopyrronium. Multidiscip Respir Med 2014; 9: 64. - PMC - PubMed
    1. Chapman KR, Beeh K-M, Bejer J, et al.. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 2014; 14: 4. - PMC - PubMed
    1. Agusti A, Hedner J, Marin JM, et al.. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011; 20(121): 183–194. - PMC - PubMed
    1. Roche N, Chavannes NH, Miravitlles M. COPD symptoms in the morning: impact, evaluation and management. Respir Res 2013; 14: 112. - PMC - PubMed
    1. Vogelmeier C, Verkindre C, Cheung D, et al.. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010; 23: 438–444. - PubMed